Immix Biopharma Inc

United States

IMMX▲

Immix Biopharma Closes $125 Million Underwritten Offering of Common Stock

Immix Biopharma has closed its previously announced underwritten registered offering of 11,363,637 shares of common stock at a public offering price of $11.00 per share, raising gross proceeds of $125 million. Net proceeds to the company, after deducting underwriting discounts, commissions and other offering expenses, were approximately $117.1 million. Immix intends to use the net proceeds to fund NXC-201 development, working capital and general corporate purposes. J.P. Morgan acted as the sole book-running manager for the offering, which included participation from leading U.S. biotechnology institutional investors and mutual funds. The shares were sold under a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on January 9, 2026, and declared effective on January 22, 2026.

IMMX ▲

IMMX · Capital · Positive Immix Biopharma closed a $125M underwritten offering, raising ~$117.1M net to fund NXC-201 development and working capital.

Read original ↗

GlobeNewswire·4dRead more →

IMMX▼

Portnoy Law Firm Investigates Immix Biopharma for Possible Securities Fraud

The Portnoy Law Firm has initiated an investigation into Immix Biopharma for possible securities fraud and may file a class action on behalf of investors. The inquiry focuses on whether the company or its leadership breached federal securities laws after media reports revealed that an executive using the alias Richard Graydon was allegedly Ronald Fischer, a top fugitive wanted in Rhode Island operating under an assumed identity. Immix disclosed that the officer was let go as of July 17, 2026, for reasons unrelated to his activities at the company, and due to his brief employment, management does not anticipate any material financial or operational impact. Following the reports, Immix's share price dropped by roughly 10.83%. Investors are encouraged to contact attorney Lesley F. Portnoy to discuss their legal rights.

IMMX ▼

IMMX · Regulation · Negative Investigation for possible securities fraud and executive's fugitive identity disclosure

Read original ↗

GlobeNewswire·75dRead more →

IMMX▼

Holzer & Holzer Investigates Immix Biopharma Over CMO Termination

Holzer & Holzer, LLC announced an investigation into whether Immix Biopharma, Inc. complied with federal securities laws. The investigation follows Immix's July 20, 2026 disclosure that it terminated its Chief Medical Officer after news reports revealed the CMO had been using a false identity and was a recently captured fugitive. The company's stock price dropped following the announcement. Investors who purchased Immix stock and suffered a loss are encouraged to contact the law firm.

IMMX ▼

IMMX · Regulation · Negative Investigation into securities law compliance and CMO termination for using false identity and being a fugitive

Read original ↗

GlobeNewswire·76dRead more →

IMMX▼

Block & Leviton Investigates Immix Biopharma for Securities Fraud Violations

Block & Leviton is investigating Immix Biopharma for potential securities law violations. The investigation follows news reports that an executive using the name Richard Graydon was allegedly a Rhode Island most-wanted fugitive named Ronald Fischer operating under a false identity. Immix stated the individual was terminated as of July 17, 2026 for reasons unrelated to his activities at the company and that his short tenure had no material effect on the business. On the day the report circulated, Immix shares fell approximately 10.83%. Investors who purchased Immix Biopharma common stock and have seen their shares fall may be eligible to participate in any potential action to recover losses.

IMMX ▼

IMMX · Regulation · Negative Investigation for securities fraud violations following revelation of executive's fugitive identity, causing 10.83% share drop.

Read original ↗

GlobeNewswire·76dRead more →